Clinical trials: Multiple Myeloma (MM), open to volunteers
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms.
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple Myeloma Refractory
- Trial name
- NCT07634263
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Multiple Myeloma (MM), CART Therapy
Neurocognitive Trajectories After BCMA CAR-T
The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).
- Conditions
- Multiple Myeloma (MM), CART Therapy, Refractory Multiple Myeloma (RRMM)
- Trial name
- CAR-T Cog (NCT07740317)
- Testing
- Standardized neurocognitive testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma (MM)
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
This phase II/III trial compares the usual treatment (daratumumab and hyaluronidase, lenalidomide, bortezomib and dexamethasone [DaraRVd] regimen followed by autologous stem cell transplant [ASCT] followed by maintenance therapy)…
- Trial name
- NCT07887984
- Testing
- Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib
- Volunteers
- 920 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Relapsed/Refractory Multiple Myeloma (MM)
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
- Trial name
- NCT07333430
- Testing
- Naive HBI0101 CAR-T
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Multiple Myeloma (MM)
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns.
- Trial name
- MFM (NCT07236502)
- Testing
- Immediate intervention, Waitlist
- Where
- 2 sites in United States
- Volunteers
- 184 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma (MM), Breathing Techniques
Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
A randomized, parallel, double-blind, controlled, clinical trial. Two groups of participants will be included, both receiving a therapeutic exercise intervention and an educational session on the importance of proper breathing…
- Conditions
- Multiple Myeloma (MM), Breathing Techniques, Breathing Exercises, Exercise Activity
- Trial name
- NCT07376733
- Testing
- Controlled breathing exercise protocol + therapeutic exercise + initial education session, Therapeutic exercise + initial education session
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Universidad Complutense de Madrid
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
This is a multicenter, prospective, single-arm, phase II clinical study evaluating the early prophylactic use of recombinant human thrombopoietin (rhTPO) to prevent thrombocytopenia associated with the EAP regimen for…
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization, Chemotherapy-Induced Thrombocytopenia
- Trial name
- NCT07848672
- Testing
- rhTPO prophylaxis plus EAP stem-cell mobilization
- Volunteers
- 70 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Plasma Cell Disorders, Multiple Myeloma (MM)
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma.
- Trial name
- NCT07660939
- Testing
- GPRC5D-Targeted PET/CT Imaging
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
The purpose of the CARMic study is to investigate whether a restrictive, microbiome-sparing antibiotic strategy can better preserve the gut microbiota in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy…
- Conditions
- Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM), Gut Microbiota
- Trial name
- CARMic (NCT07842198)
- Testing
- ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Zealand University Hospital
Multiple Myeloma (MM)
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in…
- Trial name
- NCT07477587
- Testing
- HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd
- Where
- 84 sites in United States, Australia and 3 more
- Volunteers
- 258 people
- Sponsor
- Shanghai Henlius Biotech
Multiple Myeloma (MM), Transplant-eligible Patients
F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma
This is a prospective, single-center, single-arm, exploratory pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of F182112 in combination with isatuximab and lenalidomide in transplant-eligible…
- Trial name
- CAREMM-009 (NCT07828522)
- Testing
- F182112 Plus Isatuximab and Lenalidomide
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM)…
- Trial name
- CAREMM-012 (NCT07585760)
- Testing
- CM336 Plus Isatuximab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma (MM)
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
This is a prospective, single-arm, exploratory Phase II clinical study evaluating the efficacy and safety of HP-001 capsules in combination with dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) with…
- Trial name
- BEYOND-MM 001 (NCT07811986)
- Testing
- HP-001, Dexamethasone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma (MM)
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
This is a multicenter, observational, retrospective-prospective study designed to validate the predictive role of advanced imaging in patients with newly diagnosed multiple myeloma (NDMM).
- Trial name
- NCT07746232
- Testing
- DW-MRI (MY-RADS/RAC score), Fat Fraction (rFF%), Clinical Data Collection
- Where
- 10 sites in Italy
- Volunteers
- 92 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma (MM), Multiple Myeloma Refractory
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM).
- Conditions
- Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- CORE-MM (NCT07637578)
- Testing
- Elranatamab, Tocilizumab
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma (MM)
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
- Trial name
- NCT07029776
- Testing
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arkansas
Multiple Myeloma (MM)
Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma
This is a prospective, single-arm, single-center interventional study designed to evaluate the safety and efficacy of Elra-Isa-VR in patients with newly diagnosed ultra-high-risk multiple myeloma.
- Trial name
- HRMM-001 (NCT07789522)
- Testing
- anti-BCMA/CD3 bispecific antibody
- Volunteers
- 15 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
CD38 Targeted -PET/ CT for Multiple Myeloma
The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT.
- Trial name
- NCT07782944
- Testing
- standard-of-care imaging (FDG PET/CT), CD38 PET/CT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guilin Medical University, China
Multiple Myeloma (MM), GI Cancer
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
The study investigates taste disorders that commonly occur during or after cancer treatment, often leading to issues such as malnutrition and treatment discontinuation.
- Conditions
- Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer)
- Trial name
- GustaborRCT (NCT07649681)
- Testing
- Gustabor server, Standard Recommendations
- Where
- 6 sites in Germany
- Volunteers
- 198 people
- Sponsor
- Wuerzburg University Hospital
Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory
BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19…
- Conditions
- Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin Lymphoma, B-cell
- Trial name
- NCT07771361
- Testing
- BAFF CAR-T
- Volunteers
- 90 people
- Sponsor
- Luminary Therapeutics